[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617626":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":42,"collaborators":10,"id":46,"slug":10,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Sohag University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"all patients diagnosed with advanced hepatocellular carcinoma eligible for ICIs",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Ahmed Karam Helmy, MSc","CONTACT","2+01090784895","ahmed011028@med.sohag.edu.eg",[18,34],{"facility":19,"status":10,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Sohag university hospitals","Sohag","Sohag Governorate","82511","Egypt","EG",{"type":26,"coordinates":27},"Point",[28,29],31.69478,26.55695,{"lat":29,"lon":28},[32],{"name":33,"role":14,"phone":15,"phoneExt":10,"email":16},"Ahmed Karam, MSc",{"facility":35,"status":10,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":36,"geoPoint":38,"contacts":39},"sSohag oncology centre",{"type":26,"coordinates":37},[28,29],{"lat":29,"lon":28},[40,41],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},{"name":13,"role":14,"phone":10,"phoneExt":10,"email":16},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Ahmed Karam Helmy","Use of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma : efficacy and outcomes","100617626",false,"NCT07321067","Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes","ICIs","Inclusion Criteria:\n\n* Adults (≥18 years) with radiologically or histologically confirmed advanced HCC\n* Candidates for systemic immune checkpoint inhibitors (e.g., atezolizumab-bevacizumab, durvalumab-tremelimumab).\n* Patients with preserved liver function. ( up to G2 using ALBI score or up to B (7 ) using Child-Pugh socring system) .\n\nExclusion Criteria:\n\n* Child-Pugh C liver function.\n* Prior liver transplantation.\n* patients with concurrent malignancies other than HCC.\n* Active autoimmune disease requiring systemic immunosuppression.","ALL","18 Years",{"count":55,"type":56},75,"ESTIMATED","12 Months","OBSERVATIONAL","the Objectives of this study are:\n\n• Primary Objective: To prospectively evaluate overall survival (OS), ICI-specific survival (OS-ICI), and progression-free survival (PFS) in patients with advanced HCC treated with immune checkpoint inhibitors.\n\nthe main question it aims to answer is: What are the clinical outcomes (overall survival, progression-free survival, and OS-ICIs) of immune checkpoint inhibitor therapy in patients with advanced hepatocellular carcinoma? Participants already taking immune checkpoint inhibitors as part of their regular medical care.",[61],"Advanced Hepatocellular Carcinoma (HCC)",[63,64],"advanced hepatocellular carcinoma","immune checkpoint inhibitors","NOT_YET_RECRUITING","2025-12-21",{"date":68,"type":69},"2026-01-06","ACTUAL",{"date":71,"type":56},"2026-01-01",{"date":73,"type":56},"2027-11-01",{"name":44,"class":6},2]